-
- Marina Noris
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Miriam Galbusera
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Sara Gastoldi
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Paolo Macor
- Department of Life Sciences, University of Trieste, Trieste, Italy;
-
- Federica Banterla
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Elena Bresin
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Claudio Tripodo
- Tumor Immunology Unit, Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy;
-
- Serena Bettoni
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Roberta Donadelli
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Elisabetta Valoti
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
-
- Francesco Tedesco
- IRCCS, Istituto Auxologico Italiano, Milan, Italy;
-
- Alessandro Amore
- Unit of Nephrology, Dialysis and Transplantation, Regina Margherita University Hospital, Turin, Italy; and
-
- Rosanna Coppo
- Unit of Nephrology, Dialysis and Transplantation, Regina Margherita University Hospital, Turin, Italy; and
-
- Piero Ruggenenti
- Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
-
- Eliana Gotti
- Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
-
- Giuseppe Remuzzi
- IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Ranica, Bergamo, Italy and “Centro Anna Maria Astori” Science and Technology Park Kilometro Rosso, Bergamo, Italy;
抄録
<jats:title>Key Points</jats:title> <jats:p>Endothelial-restricted complement activation occurs in aHUS, and clinical remission relies on efficient endothelial complement inhibition. Ex vivo serum-induced endothelial C5b-9 deposits are a sensitive tool to monitor complement activation and eculizumab effectiveness in aHUS.</jats:p>
収録刊行物
-
- Blood
-
Blood 124 (11), 1715-1726, 2014-09-11
American Society of Hematology